Leah Lawrence

Leah Lawrence is a freelance health writer and editor based in Delaware.

Articles by Leah Lawrence

Leah LawrencePrint | November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Leah LawrencePrint | October 8, 2024
While research on CHIP has gained momentum in recent years, treating the premalignant condition remains in debate.
Leah LawrencePrint | August 26, 2024
Following FDA approval, luspatercept and imetelstat are propelling the MDS treatment landscape forward.
Leah LawrenceTransplantation & Cellular Therapy | May 22, 2024
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
Leah LawrenceChronic Lymphocytic Leukemia | May 17, 2024
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
Leah LawrenceChronic Lymphocytic Leukemia | May 17, 2024
The ELCLV3-21  high-risk signature distinguished those with MBL with a high probability of progression.
Leah LawrenceChronic Lymphocytic Leukemia | August 23, 2024
In single-cell resolved multi-omics analyses, T-bet expression in CLL cells correlated with longer overall patient survival.
Leah LawrenceMyeloma | February 8, 2024
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Leah LawrencePrint | January 4, 2024
Shortages of essential drugs are not new, with one expert describing it as a “whack-a-mole” problem.
Leah LawrenceMyelodysplastic Syndromes | December 13, 2023
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Leah LawrenceTransplantation & Cellular Therapy | February 8, 2024
Here’s what they add to the treatment toolbox for hematologic malignancies.
Leah LawrenceMyeloma | February 8, 2024
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Leah LawrenceMyelofibrosis | February 8, 2024
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | February 8, 2024
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah LawrenceMantle Cell Lymphoma | September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Leah LawrenceMeeting News | September 10, 2023
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
Leah LawrenceMeeting News | September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Leah LawrenceAcute Lymphoblastic Leukemia | September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Leah LawrenceMeeting News | September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.